Development and optimisation of downstream processing for next generation biotherapeutics

近年来，基于蛋白质的“下一代”疗法发展迅速，但仍然需要新的制造工艺，以医疗保健提供者能够负担得起的价格提供这些疗法。这些新疗法第一次可以安全地修改患者的DNA，或利用人体自身的免疫系统来治疗遗传性疾病、神经疾病和癌症。然而，为了实现这一临床功能，治疗蛋白的复杂性和大小都增加了。这意味着现有的净化技术已经无法有效地应用于这一新的应用领域。该项目旨在建立在现有合作和可行性数据的基础上，开发可应用于一系列下一代生物疗法的新的净化工具和策略，使其能够以医疗保健支付者可接受的价格向患者提供具有成本效益的制造。

In recent years there has been rapid development of a "Next Generation" of protein-based therapeutics, yet the need remains for new manufacturing processes that can deliver these at a price healthcare providers can afford. For the first time these new therapies can safely modify a patient's DNA, or harness the body's own immune system, to treat inherited diseases, neurological conditions, and cancer. However, to achieve this clinical functionality the complexity and size of the therapeutic protein has increased. This has meant that existing purification technologies have been unable to be applied effectively in this new application. This project aims to build on existing collaborations and feasibility data to develop new purification tools and strategies that can be applied across a range of next generation biotherapeutics to enable their cost effective manufacture delivering novel therapies to patients at an aceeptable price for healthcare payers.